Research programme: pancreatic disorder therapeutics - Sun BioPharmaAlternative Names: SBP-102
Latest Information Update: 18 Sep 2015
At a glance
- Originator University of Florida
- Developer Sun BioPharma
- Class Polyamines
- Mechanism of Action Apoptosis stimulants; Cell division inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer; Pancreatitis
Most Recent Events
- 16 Sep 2015 Preclinical trials in Pancreatitis in USA (SC) before September 2015